| Bioactivity | Mardepodect (PF-2545920) is a potent, orally active and selective PDE10A inhibitor with an IC50 of 0.37 nM, with >1000-fold selectivity over other PDEs. Mardepodect can cross the blood-brain barrier[1][2]. | ||||||||||||
| In Vivo | In the conditioned avoidance response assay (CAR), Mardepodect (PF-2545920) is active with an ED50 of 1 mg/kg. Administration of Mardepodect (PF-2545920) to mice causes a dose dependent increase in striatal cGMP[2]. | ||||||||||||
| Name | Mardepodect | ||||||||||||
| CAS | 898562-94-2 | ||||||||||||
| Formula | C25H20N4O | ||||||||||||
| Molar Mass | 392.45 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Verhoest PR, et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J Med Chem [2]. Grauer SM, et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther, 2009, 331(2), 574-590. |
Mardepodect
CAS: 898562-94-2 F: C25H20N4O W: 392.45
Mardepodect (PF-2545920) is a potent, orally active and selective PDE10A inhibitor with an IC50 of 0.37 nM, with >1000-f
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.